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DISCLAIMER
DISCLAIMER – FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN
RISK
The protocol content here is for informational purposes only and does not
constitute legal, medical, clinical, or safety advice, or otherwise; content added
to protocols.io is not peer reviewed and may not have undergone a formal
approval of any kind. Information presented in this protocol should not
substitute for independent professional judgment, advice, diagnosis, or
treatment. Any action you take or refrain from taking using or relying upon the
information presented here is strictly at your own risk. You agree that neither
the Company nor any of the authors, contributors, administrators, or anyone
else associated with protocols.io, can be held responsible for your use of the
information contained in or linked to this protocol or any of our Sites/Apps and
Services.
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ABSTRACT
Ultrasound is a sound wave with frequencies ranging between 20 kHz and 20 MHz.
Ultrasound is able to temporarily and repeatedly open the BBB safely and enhance
chemotherapeutic delivery without adverse effects.(Deprez et al., 2021). This novel
technique in drug delivery benefits from the powerful ability of ultrasound to produce
cavitation activity. Cavitation is the generation and activity of gas-filled bubbles in a
medium exposed to ultrasound. As the pressure wave passes through the media,
gas bubbles expand at low pressure and contract at high pressure. This leads to
oscillation which produces a circulating fluid flow known as microstreaming around
the bubble with velocities and shear rates proportional to the amplitude of the
oscillation. At high amplitudes the associated shear forces can cut open liposomes
(Wanigasekara et al., 2021; Deprez et al., 2021).
Vesicles denser than the surrounding liquid are drawn into the shear field
surrounding an oscillating bubble. If the shear stress is greater than the strength of
the vesicle, it will burst and spill its contents. In a liposome, the vesicle will reform,
often at a smaller size than before meeting the shear field. Hence, some interior
liquid must be released during the break down. (Pitt et al., 2004)
This protocol describes the use of an ultrasound probe to trigger the release of
liposomes in glioblastoma cells. This method uses an ultrasound device which is set
to the following parameters: Time = 3 min, Pulse = 59 /01, Amplitude = 20%. The
ultrasound technique is an easy and reliable technique making it useful in the study
of a variety of areas such as oncology. When applied to an ultrasonic transducer, the
Pulser part of the instrument generates short, large amplitude electric pulses of
controlled energy, which are transformed into short ultrasonic pulses.
The VCX 750 is the ultrasonic liquid processor used for this experiment. It is powerful
and versatile and can process a wide range of sample types and volumes for many
different applications.
MATERIALS TEXT
VCX 750 ultrasonic liquid processor
96 probe system
96 well plate
retort stand
laboratory Jack
Sonics - Vibra cell power unit
96-well seed plate
Nunclon™ Sphera™ 96-Well plate
Incubator
Fresh media
Dimethyl sulfoxide (DMSO) (20%)
SAFETY WARNINGS
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Laboratory coat and gloves must be worn at all times.
Ear protection must be worn at all times due to the highfrequency sound level of the VCX 750 ultrasonic liquid
processor.
A safe distance must be kept between the operator and the
VCX 750 ultrasonic liquid processor while in operation.
Ensure there is signage advising others that an ultrasound
device is in operation.

1

Before starting the ultrasound probe system, ensure that all parts of the system/device are free
from mechanical damage and that the probe is connected tightly.
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2

Image of the VCX 750 ultrasonic liquid processor

The 96-probe system is designed to fit perfectly into the 96 well plate, which can be used to grow
and treat cancer cells. The retort stand is used to hold the Ultrasound 96 probe unit vertically. A
laboratory Jack is used to hold the cancer cells grown in the 96 well plate and to move it towards
the 96 probes.
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A Sonics - Vibra cell power unit is needed to fix into ultrasound 96 probe. Using the power unit, the
ultrasound treatment time (0 to 99 min), temperature, pulser, and amplitude can be controlled.
Experiments found that the best parameters to use are 20% amplitude, Pulses of 59 seconds on
and 1 second off with different time ranges (1, 3, 5, 10, and 20 min).

Data processor unit showing the experiment parameters

4

For 2D cell culture assays using a 96-well seed plate, seed cells in 100 μl of the appropriate
media. For 3D cell culture assays using a Nunclon™ Sphera™ 96-Well plate, seed cells in 200 μl of
the appropriate media. Leave 2D cells to adhere overnight at 37 ℃ in a humidified atmosphere at
a density of 2 x 10^3 cells/well or 1 x 10^4 cells/well for 96 hours incubation time post-treatment
and 24 hours incubation time post-treatment, respectively. During 3D cells, spheroids will usually
form in 3-7 days from the starting date depending on seeding density.

5

On the day of ultrasound treatment, remove the culture media from the plates and add 100µl
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fresh media into each plate. It is Important that during ultrasound treatment all the 96 probe tips
are immersed inside media/ any liquid). There mustn't be any empty wells, hence 100ul of media
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Ultrasound probe submerged in sample
should be added into each well.

6

Place the sample (plate without lid) in the centre of the laboratory Jack and slowly move into the
96 probe. 2mm distance must be kept from the bottom of the well to the probe tip during the
treatment. After setting up the unit, the device is turned on. The samples are treated with the
ultrasound using the parameters that were set.

7

Following treatment, remove the sample plates from the probe system and carry out post
treatment incubation at 37 ℃ using 5% CO2. Dimethyl sulfoxide (DMSO) (20%) is used as a
positive control. Ultrasound treated cells / tumorspheres are then used for further analysis.
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